CAR T-cell therapy is a promising treatment for patients with many types of blood cancer, including leukemia. It is a highly-specialized therapy that involves genetically modifying a patient's own T cells to attack their cancer.
CAR T-cell therapy is FDA-approved for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).
Patients are evaluated carefully to determine if this therapy is appropriate for them, and are cared for by a team experienced in CAR T-cell therapy.
In addition to the FDA-approved therapy, Dana-Farber Brigham Cancer Center also offers clinical trials evaluating CAR T-cell therapy for other types of leukemia, as well as other blood cancers.
Key Eligibility Criteria for CAR T-Cell Therapy for Leukemia
Key eligibility criteria include:
- Confirmed diagnosis of B-cell acute lymphoblastic leukemia (ALL) that has either not responded or has relapsed after one line of prior treatment.
- Adequate organ, cardiac, and pulmonary function (must meet established criteria/measures).
Children and young adults may also be evaluated at Dana-Farber/Boston Children's Cancer and Blood Disorders Center (Dana-Farber/Boston Children's).